ARA-290 Peptide Overview
ARA-290 is a peptide that has been engineered from erythropoietin (EPO). It is a nonhematopoietic peptide designed to interact selectively with the innate repair receptor, which mediates tissue protection. Here is an overview of ARA-290:
- ARA-290 is an 11-amino acid peptide that is based on the structure of helix B of the EPO molecule.
- It has shown efficacy in preclinical and clinical studies of metabolic control and neuropathy.
- ARA-290 has undergone extensive evaluation in various preclinical models, including those for insulin resistance, diabetic retinopathy, diabetic autonomic neuropathy, myocardial infarction, chronic heart failure, burns, traumatic brain injury, and shock-induced multi-organ failure.
- It has been found to prevent tissue damage, reduce inflammation, and promote healing.
- ARA-290 is a linear peptide consisting of 11 amino acids and has a molecular weight of 1257 daltons.
- ARA-290 has completed phase II trials and is now preparing for phase III trials in the treatment of conditions such as diabetes and autoimmune sarcoidosis.
- It has potential applications in treating neuropathic pain, promoting wound healing in chronic diabetes, modulating the immune system, and managing systemic lupus erythematosus.
- ARA-290 provides pain relief and neuroprotection without stimulating red blood cell production.
- It has been shown to reduce inflammation, chronic pain, and promote healing.
ARA-290 Peptide Structure
PubChem CID: 91810664
Molecular Formula: C51H84N16O21
Synonyms: Cibinetide, ARA290, 1208243-50-8, PHBSP, PH-BSP
Molecular Weight: 1257.3 g/mol
ARA-290 and Inflammation
ARA-290 is a peptide that has been extensively studied for its impact on inflammation and pain relief. Here is an overview into research on the effects of ARA-290 on inflammation:
- ARA-290 exhibits analgesic properties by exerting anti-inflammatory and immunomodulatory functions. It specifically targets the innate repair receptor (IRR) to reduce inflammation and alleviate neuropathic pain.
- Activation of the IRR through ARA-290 triggers a localized anti-inflammatory response and facilitates tissue repair. It can inhibit cell death signals, prevent tissue damage, and promote the growth of nerve fibers in the nervous system.
- Animal studies have demonstrated that ARA-290 possesses tissue-protective effects and can effectively reduce inflammation. It has shown promise in improving survival rates after myocardial infarction, mitigating organ dysfunction in hemorrhagic shock, and suppressing the development of atherosclerosis.
- ARA-290 has been extensively evaluated in various preclinical models and has consistently demonstrated its ability to prevent tissue injury, reduce inflammation, and promote healing. It has been investigated in conditions such as diabetic retinopathy, burns, traumatic brain injury, and multi-organ failure.
- Research has revealed that ARA-290 can reduce inflammation in nerves, stimulate the formation of new blood vessels, decrease cytokine levels, and inhibit the inflammatory cytokine TNF-a. It also exhibits anti-inflammatory effects on Schwann cells and promotes their proliferation.
ARA-290 and Tissue Protection
ARA-290 is a non-erythropoietic peptide that is designed to activate the innate repair receptor (IRR) and mediate tissue protection. It reduces inflammation and fibrotic responses by signaling through a receptor composed of EPOR and CD131, the β common cytokine receptor. ARA-290 prevents tissue injury, reduces inflammation, and promotes healing. It works by activating the IRR, which inhibits the production and action of proinflammatory cytokines. In preclinical injury models, ARA-290 inhibits TNFα and other proinflammatory cytokines.
ARA-290 possesses tissue-protective and tissue-regenerative properties. It interacts with the innate repair receptor to promote tissue repair, reduce inflammation, and prevent cell death. ARA-290 selectively targets the innate repair receptor to exert its regenerative effects on various body tissues. Extensive scientific evidence supports the beneficial effects of ARA-290 on different types of tissue injuries. In rat studies, ARA-290 effectively protected against early renal allograft injury by reducing macrophage infiltration. Additionally, ARA-290 has been shown to attenuate small nerve fiber loss and neuritis associated with type 2 diabetes-induced neuropathy.
ARA-290 and Pain Relief
ARA-290, a peptide derived from erythropoietin, has been studied for its potential in providing pain relief, specifically in neuropathic pain conditions. The search results indicate the following findings regarding ARA-290 and pain relief:
- ARA290 activates the β-common receptor, leading to long-term relief of allodynia, a type of pain sensitivity. It is believed that the anti-inflammatory properties of ARA290, possibly within the central nervous system, contribute to the relief of neuropathic pain associated with its treatment.
- ARA290 shows promise as a drug for preventing peripheral nerve injury-induced neuropathic pain in humans, as it does not have hematopoietic and cardiovascular side effects.
- According to a study, more frequent dosing of ARA290 may be necessary to prevent an increase in pain over time, given its biologic half-life of less than 1 week.
- ARA290 has demonstrated analgesic and tissue protective effects in various diseases such as diabetes and cancer.
- In patients with type 2 diabetes, ARA290 has shown potential in improving metabolic control and alleviating neuropathic symptoms.
- ARA290, as an innate repair receptor (IRR) agonist, has been associated with increased energy and pain relief.